28th Annual International Mental Health Research Symposium

Friday, October 28, 2016
28th Annual International Mental Health Research Symposium

The 28th Annual International Mental Health Research Symposium featured the 2016 Outstanding Achievement Prizewinners and select Young Investigators presenting updates on leading research discoveries across brain and behavior disorders, and a Special Keynote Presentation

Keynote Speaker:

Robert O. Boorstin - Senior Vice President, Albright Stonebridge Group

A Search for Balance: Personal & Political Reflections on Mental Health

Presented by 
Michael F. Green, Ph.D.
Michael F. Green, Ph.D.
University of California, Los Angeles

Professor, Semel Institute for Neuroscience and Human Behavior

2016 Lieber Prizewinner for Outstanding Achievement in Schizophrenia Research

 

<p>Dr. Green’s clinical research laboratory explores the relationship between cognitive and social cognitive impairments in schizophrenia and activities of daily living. His team also explores the neural mechanisms of cognitive and social cognitive dysfunction in schizophrenia and bipolar disorder. Dr. Green is a leading researcher in the evaluation of social cognitive retraining and novel pharmacological interventions to improve cognitive impairments. His laboratory also studies the determinants of community integration for homeless veterans, many of whom have psychotic disorders. His identification of the importance of cognition in schizophrenia launched the national Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) effort, and stimulated novel and innovative treatments for cognitive dysfunction.</p> <hr /> <h4>Prizewinner Video:</h4> <p>&nbsp;</p> <p><iframe frameborder="0" height="400" src="https://www.youtube.com/embed/sD629nm2KaQ?rel=0" width="100%"></iframe></p>


Symposium Presentation:

Seeing, Feeling, and Inferring the Social World in Schizophrenia
October 28, 2016, New York City

Stephen R. Marder, M.D.
Stephen R. Marder, M.D.
University of California, Los Angeles

Professor, Psychiatry and Biobehavioral Sciences

Director, Section on Psychosis

2016 Lieber Prizewinner for Outstanding Achievement in Schizophrenia Research

 

<p>During his career, Dr. Marder has focused on pharmacological and non-pharmacological approaches to improving the outcomes of serious mental illnesses, particularly schizophrenia. His clinical intervention research began with studies that evaluated strategies for reducing adverse side effects of antipsychotic medications, and studies that evaluated the interactions of psychosocial interventions and pharmacological approaches to improving the outcome of serious mental illnesses. Together with Dr. Green, his fellow Lieber Prize recipient, he led the NIMH-MATRICS initiative, which addressed key issues in the development of medications for improving cognition in schizophrenia.</p> <hr /> <h4>Prizewinner Video:</h4> <p>&nbsp;</p> <p><iframe frameborder="0" height="400" src="https://www.youtube.com/embed/n6DYu8__2Co?rel=0" width="100%"></iframe></p>


Symposium Presentation:

Improving Functioning in People With Psychotic Illness: A New Goal for Treatment Research
October 28, 2016, New York City

William P. Horan, Ph.D.
William P. Horan, Ph.D.
University of California, Los Angeles

Research Psychologist

2016 Maltz Prizewinner for Outstanding Achievement in Innovative & Promising Schizophrenia Research

 

<p>Dr. Horan conducts translational research to identify factors that contribute to difficulties in community integration among people with schizophrenia and other forms of psychosis, and has been a leader in the development of innovative treatments that may help patients improve the quality of their lives. More recently, he has begun applying this translational research approach to investigations of bipolar disorder and homelessness. In addition, he has focused on the development and validation of the Social Cognitive Skills Training Program for people with psychosis. The goal of this research is to develop new treatments that enable people with psychosis to live independently, pursue personally meaningful vocational and educational goals, and develop more satisfying social networks in the community. His work has led to a deeper understanding of the impairments in motivation and social behaviors that affect the lives of many people with schizophrenia, previously viewed by most clinicians as untreatable, and led to a new sense of optimism that these problems can be addressed in the clinic.</p> <hr /> <h4>Prizewinner Video:</h4> <p>&nbsp;</p> <p><iframe frameborder="0" height="400" src="https://www.youtube.com/embed/nODp838wDCo?rel=0" width="100%"></iframe></p>


Symposium Presentation:

Developing Interventions to Enhance Social Congnition in Schizophrenia
October 28, 2016, New York City

Amanda McCleery, Ph.D.
Amanda McCleery, Ph.D.

Assistant Professor, Psychological and Brain Sciences

University of Iowa

2016 Maltz Prizewinner for Innovative and Promising Schizophrenia Research

2015 Young Investigator Grant

 

<p>Dr. McCleery’s research focuses on cognitive predictors of functional outcome in schizophrenia and related conditions. Her recent work uses EEG techniques in conjunction with performance-based measures to better understand the nature of the relationships between early-stage information processing, higher-order cognition, and community functioning across phases of illness in schizophrenia.&nbsp; Her work is also informed by developmental psychopathology in order to gain a nuanced understanding of the trajectory of cognition over the course of illness to identify potential critical periods and targets for intervention, as well as possible mechanisms of change.</p> <hr /> <p>&nbsp;</p> <h4>Prizewinner Video:</h4> <p>&nbsp;</p> <p><iframe frameborder="0" height="400" src="https://www.youtube.com/embed/8OaSwTS7NWc?rel=0" width="100%"></iframe></p>


Symposium Presentation:

Neuroplasticity in Schizophrenia: How to Measure it and What Does it Mean?
October 28, 2016, New York City

Thomas G. Schulze, M.D.
Thomas G. Schulze, M.D.
Medical Center of the University of Munich / Johns Hopkins University / National Institute of Mental Health (NIMH)

Professor and Director, Institute of Psychiatric Phenomics and Genomics (IPPG)

Adjunct Faculty, Department of Psychiatry and Behavioral Sciences

Associate Investigator Human Genetics Branch

2002, 2007 Young Investigator Grantee

 

<p>Dr. Schulze’s research focuses on genotype-phenotype relationships in psychiatric disorders. He coordinates a German-wide center grant on longitudinal psychosis research and spearheads an international study on the genetic basis of response to lithium treatment in bipolar disorder, comprising several research groups from Europe, the Americas, Africa, Asia, and Australia. In addition, he and his team have embarked on population-based genetic studies in Ethiopia, focusing on the interplay of khat abuse (a plant that is used as a drug), trauma, and psychosis. Within the framework of a German government-funded, multi-site network, he is entrusted with the job of setting up a national federated biobanking and phenotyping platform.</p> <hr /> <h4>Prizewinner Video:</h4> <p>&nbsp;</p> <p><iframe frameborder="0" height="400" src="https://www.youtube.com/embed/IP9NtH6mTsc?rel=0" width="100%"></iframe></p>


Symposium Presentation:

Exploring the Phenotypic Complexity in Psychiatric Genetics: From Pharmacoresponse to Illness Trajectories
October 28, 2016, New York City

Francis J. McMahon, M.D.
Francis J. McMahon, M.D.
National Institute of Mental Health (NIMH)

Senior Investigator

2006, 1998 Independent Investigator Grantee

1994 Young Investigator Grantee

2016 Colvin Prizewinner for Outstanding Achievement in Mood Disorder Research

 

<p>Dr. McMahon’s research is aimed at discovering and characterizing genes involved in mood and anxiety disorders in order to develop better methods of diagnosis and treatment. For more than a decade, his work has focused on pharmacogenomics, including genetic studies of antidepressant outcome, lithium response, and treatment-resistant depression. Still in its early stages, pharmacogenomics underlies the increasing interest in personalized and precision medicine, promising to reduce trial and error in the selection of the most effective treatments, while minimizing adverse events.</p> <hr /> <h4>Prizewinner Video:</h4> <p>&nbsp;</p> <p><iframe frameborder="0" height="400" src="https://www.youtube.com/embed/duEbIc-mRXA?rel=0" width="100%"></iframe></p>


Symposium Presentation:

Seeing the World in a Grain of Sand: Making Sense of the Many Genes that Underlie Bipolar Disorder
October 28, 2016, New York City

Earl K. Miller, Ph.D.
Earl K. Miller, Ph.D.
Massachusetts Institute of Technology

Picower Professor of Neuroscience

2016 The Goldman-Rakic Prizewinner for Outstanding Achievement in Cognitive Neuroscience

 

<p>Building on Pat Goldman-Rakic’s groundbreaking studies, Dr. Miller’s work in primates has broken new ground in the understanding of cognition. Using innovative experimental and theoretical approaches to study the neural basis of high-level cognitive functions, his laboratory has provided insights into how categories, concepts, and rules are learned, how attention is focused, and how the brain coordinates thought and action. The laboratory has innovated techniques for studying the activity of many neurons in multiple brain areas simultaneously, providing insight into how different brain structures interact and collaborate. This work has established a foundation upon which to construct more detailed, mechanistic accounts of how executive control is implemented in the brain and its dysfunction in diseases such as autism, schizophrenia and attention deficit disorder, and has led to new approaches relevant to severe mental illnesses in children and adults.</p> <hr /> <h4>Prizewinner Video:</h4> <p>&nbsp;</p> <p><iframe frameborder="0" height="400" src="https://www.youtube.com/embed/_HxD5ORVQqo?rel=0" width="100%"></iframe></p>


Symposium Presentation:

Cognition is Rhythmic
October 28, 2016, New York City

John L.R. Rubenstein, M.D., Ph.D.
John L.R. Rubenstein, M.D., Ph.D.
University of California at San Francisco

Nina Ireland Distinguished Professor in Child Psychiatry

Nina Ireland Laboratory of Developmental Neurobiology

Center for Neurobiology and Psychiatry, Department of Psychiatry

Scientific Council Member Emeritus

2016 Ruane Prizewinner for Outstanding Achievement in Child and Adolescent Psychiatric Research

1997 Distinguished Investigator Grant

1992, 1990 Young Investigator Grant

 

Dr. Rubenstein's basic research interest is in developmental neurobiology, particularly the development of the forebrain, the area of the brain that is required for the highest intellectual functions. His clinical interest is in neurodevelopmental disorders. Early in his career, Dr. Rubenstein applied his training in biophysics to basic explorations of membrane structure and biogenesis. Later, he used antisense RNA and retroviral vectors, advanced techniques for manipulating genetic information, to study the molecular and cellular mechanisms of embryogenesis.

Dr. Rubenstein trained at Stanford University and the Pasteur Institute in Paris prior to joining UCSF. While serving as a resident physician at Stanford Medical School, he began experiments on the genetic control of forebrain development that remain the focus of his work at UCSF, where he examines genetic mechanisms underlying epilepsy and cognitive disorders.


Prizewinner Video:

 


Symposium Presentation:

Genetic Analyses of Forebrain Development Give Insights into Origins of Neuropsychiatric Disorders
October 28, 2016, New York City

Moderated by
Robert M.A. Hirschfeld, M.D.
Weill Cornell Medical College, Cornell University

2003 Falcone Prize for Outstanding Achievement in Affective Disorders Research (Colvin Prize)

2002 Distinguished Investigator Grant

 

Dr. Hirschfeld’s research has significantly contributed to understanding the classifications of depression and bipolar disorders; their clinical course, relationship to personality and personality disorders and treatment with medication and psychotherapy. He and his colleagues developed the Mood Disorder Questionnaire, the most widely used screening instrument for bipolar disorder.

Dr. Hirschfeld chaired the original and revised versions of the American Psychiatric Association’s working group to develop practice guidelines for treatment of patients with bipolar disorder. He was Chief of the Mood, Anxiety and Personality Disorders Research Branch and Clinical Director of the Depression Awareness, Recognition and Treatment (D/ART) Program of the NIMH.